Analyst reactions to Amazon's pharma acquisition

By Bailey Lipschultz | June 29, 2018 at 10:49 AM

While speculation about Amazon entering the health-care space has plagued the sector for months, one analyst calls the latest move “a full frontal attack.”

plans to buy speculation Related: Health companies race to catch UnitedHealth as Amazon laces up

Robert W. Baird health supply-chain analyst, Eric Coldwell

Evercore ISI health tech and distribution analyst, Ross Muken

RBC Capital Markets health-services analyst, George Hill

Mizuho health services analyst, Ann Hynes

Bloomberg Intelligence, Jitendra Waral and Charles Allen

Copyright 2018 Bloomberg. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

NOT FOR REPRINT

© Touchpoint Markets, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to TMSalesOperations@arc-network.com. For more information visit Asset & Logo Licensing.

Recommended Stories

May 06, 2026

Aetna, meanwhile, is talk about its efforts to adopt a low-friction prior authorization strategy.

May 06, 2026

The framework links U.S. drug prices to international benchmarks through manufacturer agreements and federal pricing mechanisms, with major implications for high-cost drugs like GLP-1s.

May 06, 2026

Fifty-four percent of workers would give up at least one workplace perk for employer-covered GLP-1 treatment.